Evoke Pharma (NASDAQ:EVOK) Share Price Crosses Below 200 Day Moving Average – Time to Sell?

Evoke Pharma, Inc. (NASDAQ:EVOK)’s stock price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.01 and traded as low as $4.30. Evoke Pharma shares last traded at $4.30, with a volume of 11,595 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Evoke Pharma in a report on Thursday. They issued a “sell” rating for the company.

Evoke Pharma Price Performance

The firm has a market cap of $6.41 million, a P/E ratio of -0.39 and a beta of 0.15. The stock’s 50-day simple moving average is $4.49 and its two-hundred day simple moving average is $5.01.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.94) earnings per share for the quarter. The firm had revenue of $2.65 million during the quarter. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned approximately 1.42% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.